Filed in archive
Cardiovascular Health
, Diagnostics
, FDA Approvals
by Gloria Gamat on August 27, 2008
AlloMap® - developed by XDx Inc. - is a non-invasive test utilizing molecular expression techniques that will help doctors in managing heart transplant patients after surgery to monitor organ rejection.
The FDA has cleared AlloMap® Molecular Expression Testing - making XDx Inc. the first U.S. molecular diagnostics company to obtain FDA clearance of an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for use in transplant management.
Organ rejection is crucial to the survival of a heart transplant patients. AlloMap® offers a non-invasive way of determining if a patient's new transplanted heart is being rejected by the immune system, as opposed to heart biopies that clinicians mainly rely on.
Read more about AlloMap® and its FDA clearance from the XDx press release (pdf file) and the FDA News.
Check out this patient page detailing the testing process and health insurance information.
The FDA has cleared AlloMap® Molecular Expression Testing - making XDx Inc. the first U.S. molecular diagnostics company to obtain FDA clearance of an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for use in transplant management.
AlloMap Testing assays the RNA levels of 11 rejection biomarker genes and nine control genes. AlloMap Testing was clinically validated using data from 9 leading heart transplant centers participating in the Cardiac Allograft Rejection Gene Expression Observational (CARGO) study.
AlloMap Test has been available since January 2005 as a Laboratory Developed Test (LDT) performed in the XDx Clinical Laboratory Improvement Amendments (CLIA) certified Laboratory, and has been ordered at more than 50 U.S. transplant centers. The AlloMap Test may be used for stable patients aged 15 years or older at any time after the second month post-transplant. In order to maintain tight control of the testing processes, AlloMap Test is currently performed only at the XDx Reference Laboratory.
Organ rejection is crucial to the survival of a heart transplant patients. AlloMap® offers a non-invasive way of determining if a patient's new transplanted heart is being rejected by the immune system, as opposed to heart biopies that clinicians mainly rely on.
Read more about AlloMap® and its FDA clearance from the XDx press release (pdf file) and the FDA News.
Check out this patient page detailing the testing process and health insurance information.
Tags:
heart
transplant
organ
rejection
immune
system
AlloMap®
Molecular
Expression
Testing
XDx
health
he
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/132520
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for AlloMap®: Novel Non-invasive Test For Managing Heart Transplant Patients:
|
Rating: 6.67 out of 3 vote(s) cast.
|
Response from:
suceel
(08/30/08 11:11am)
Very Informative post,its a great achievement in field of health..
Response from:
suceel
(08/30/08 11:22am)
Great achievement in field of medicine.. Thanks for the information
Response from:
Trusted.MD Network
Response from:
JabberTags - Find New Sites and Explore the Internet
Bookmarked your site as oral at JabberTags!
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
